Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 19/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 18/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.48 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.48 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.48 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3608862 | 0.83 | TRPM8 (0.42) | HDAC6HDAC1HDAC8HDAC3HDAC7 | |
| SCHEMBL3602101 | 0.78 | NPC1 (0.50) | — | |
| SCHEMBL3608838 | 0.77 | CYP2C9 (0.54) | — | |
| SCHEMBL3612223 | 0.76 | HDAC6 (0.83) | HDAC6HDAC1HDAC8HDAC3HDAC7 | |
| SCHEMBL3610564 | 0.76 | HDAC6 (0.63) | HDAC6HDAC1HDAC8HDAC3HDAC7 | |
| SCHEMBL1855827 | 0.74 | NAAA (0.47) | HDAC6HDAC1HDAC3HDAC2NCOR2 | |
| SCHEMBL3608521 | 0.73 | HDAC6 (0.54) | HDAC6HDAC1HDAC8HDAC3HDAC7 | |
| SCHEMBL3608552 | 0.73 | SLC6A7 (0.57) | — | |
| SCHEMBL20132429 | 0.73 | HDAC6 (0.51) | HDAC6HDAC1HDAC8HDAC3HDAC10 | |
| SCHEMBL3607450 | 0.72 | HDAC6 (0.61) | HDAC6HDAC1HDAC8HDAC3HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | claimed |
| US-20100152188-A1 | Novel Heterocyclic Compounds | ORCHID RESEARCH LABORATORIES LIMITED (IN) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152188-A1 | Novel Heterocyclic Compounds | CYP11B2, CYP3A5, CYP11B1 | HDAC6 90/4885HDAC1 307/4885HDAC8 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.